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Aberrant DNA methylation patterns in malignant
cells allow insight into tumor evolution and develop-
ment and can be used for disease classification.
Here, we describe the genome-wideDNAmethylation
signatures of NPM-ALK-positive (ALK+) and NPM-
ALK-negative (ALK) anaplastic large-cell lymphoma
(ALCL).Wefind thatALK+andALKALCLsharecom-
mon DNA methylation changes for genes involved in
T cell differentiation and immune response, including
TCR and CTLA-4, without an ALK-specific impact on
tumor DNA methylation in gene promoters. Further-
more, we uncover a close relationship between global
ALCL DNA methylation patterns and those in distinct
thymic developmental stages and observe tumor-
specific DNA hypomethylation in regulatory regions
that are enriched for conserved transcription factor
binding motifs such as AP1. Our results indicate
similarity between ALCL tumor cells and thymic
T cell subsets and a direct relationship between
ALCL oncogenic signaling and DNA methylation
through transcription factor inductionandoccupancy.
INTRODUCTION
Anaplastic large-cell lymphoma (ALCL) is a category of non-
Hodgkin lymphoma (NHL) and is of T cell origin. ALCL is mostly
diagnosed in children and young adults and represents 10%–
15% of pediatric and adolescent NHL (Greer et al., 1991; Stein
et al., 1985). A specific translocation (t(2;5)(p23q35)) involving596 Cell Reports 17, 596–608, October 4, 2016 ª 2016 The Author(s)
This is an open access article under the CC BY license (http://creativefusion of the ubiquitously expressed nucleolar shuttling pro-
tein Nucleophosmin (NPM1) to the receptor tyrosine kinase
anaplastic lymphoma kinase (ALK) is detected in more than
30% of ALCL cases (Morris et al., 1994). This translocation leads
to the expression of the constitutively active NPM-ALK kinase,
which is a potent trigger of multiple signaling pathways and is suf-
ficient to drive cells toward malignant transformation (Bischof
et al., 1997; Chiarle et al., 2003; Fujimoto et al., 1996; Turner
etal., 2003). InNPM-ALK-positive (ALK+)ALCL, it hasbeenshown
that most changes leading to cell transformation are induced by
transcription factors (TFs) such as STAT3/5, CEBPB, and AP1
(Leventaki et al., 2007; Mathas et al., 2002; Piva et al., 2006;
Rassidakis et al., 2005; Turner et al., 2007; Zamo et al., 2002). In
NPM-ALK-negative (ALK) ALCL, recurrent driver mutations
in JAK1 and STAT3 genes, as well as chimeras combining TFs
with tyrosine kinases (ROS1 or TYK2) and overexpression of trun-
cated ERBB4 transcripts, have been described (Crescenzo et al.,
2015; Scarfo` et al., 2016). ALK ALCL shows a more heteroge-
neous genome in terms of somatic mutations and fusion tran-
scripts, and gene expression studies indicate that ALK+ ALCL
and ALK ALCL display similar signatures, thus suggesting a
common cell of origin (Boi et al., 2015; Eckerle et al., 2009).
Epigenetic alterations in cancer cells typically comprise global
loss and local gain of DNA methylation (Egger et al., 2004). The
latter has its largest impact on gene expression when found at
promoter sites, because methylation at these sites is associated
with silencing of the underlying genes. Changes in the methyl-
ome of malignant tissue contribute to dysfunctional gene
expression and regulation. In addition, it has been shown that
DNA methylation fingerprints of cancer tissues share distinct
methylated sequences with their tissues of origin that make it
possible to identify the stage of differentiation most closely
related to the tumors and enable prediction of the cell of origin.
commons.org/licenses/by/4.0/).
by epigenetic memory, which can be more reliable than by gene
expression (Fernandez et al., 2012).
In ALK+ ALCL, only a few aberrantly methylated genes,
including components of the T cell receptor (TCR) pathway
and genes important for cell proliferation and survival, such as
p16INK4A, TNF-a,NFATC1, IL-2R, and BIM, have been identified;
even less is known about specific methylation changes in ALK
ALCL (Akimzhanov et al., 2008; Ambrogio et al., 2009; Martin-
Subero et al., 2009; Nagasawa et al., 2006; Piazza et al., 2013;
Zhang et al., 2009, 2011). Mechanistically, the TF STAT3 has
been implicated in epigenetic silencing by upregulating and re-
cruiting DNMT1 to promoters of some of the silenced genes in
ALK+ ALCL (Zhang et al., 2005, 2007). However, no comprehen-
sive genome-wide analysis of DNA methylation in ALCL has
been conducted. In addition, it is unknownwhether the presence
of the ALK oncogene has an impact on DNAmethylation in ALK+
compared to ALK lymphomas.
Controversy also exists about the cell of origin of ALCL. Histor-
ically, mature T cells were presumed to be the targets for trans-
formation, based on gene expression profiling and the presence
of surface markers such as CD4 or CD30, as well as production
of cytotoxic proteins such as Granzyme B and Perforin (Benhar-
roch et al., 1998; Eckerle et al., 2009; Swerdlow et al., 2008).
However, ALK+ cells are present in stem cell-enriched cord
blood, and a study has identified a side population of cells in
ALK+ ALCL cell lines and tumors with signatures similar to early
thymic progenitors (ETPs), suggesting that transformation of
T cells by NPM-ALKmight occur early during thymic T cell devel-
opment (Laurent et al., 2012; Moti et al., 2015). Subsequently, a
mechanism has been proposed whereby in a murine mimic of
ALK+ ALCL transient expression of a functional TCR is required
for thymic emigration of incipient, thymic-resident tumor cells,
but the TCR is then downregulated for peripheral lymphomagen-
esis (Malcolm et al., 2016).
We reasoned that a comprehensive study of the ALCLmethyl-
omemight help to elucidate the impact of ALK-specific signaling
on the epigenome of ALK+ ALCL in relation to ALK ALCL and
allow for a better classification of ALCL tumor cells with regard
to their cellular origin.
RESULTS
Identification ofMethylation Variable Positions between
Primary ALCL and Healthy Activated CD3+ T Cells
We performed DNA methylation profiling of human ALK+ (n = 5)
and ALK (n = 5) tumors and peripheral blood activated CD3+
T cells from healthy donors (n = 5) using the Illumina Infinium
HumanMethylation450 BeadChip, which covers 482,421 CpG
dinucleotides and 99% of RefSeq genes. An overview of the
data analysis process is depicted in Figure S1.
After data normalization and quality control steps, we identified
42,752 and 12,354 significant methylation variable positions
(MVPs) between tumor (ALK+ or ALK) and normal control
(CD3+ T cells) (based on M value calculation and adjusted p <
0.01) (Figure 1A). Comparison of ALK+ to ALK tumors revealed
18,291 significant MVPs. To perform hierarchical clustering
and investigate the relationship among ALK+, ALK, and CD3+
samples, we next filtered these MVPs with filtering criteria of anadjusted p < 0.01 and b-value difference > 0.2. Hierarchical clus-
tering of ALK+ versus CD3+ cells (31,580 CpG sites) resulted in a
distinct ALK+ cluster (except for one tumor) that appeared more
distant to ALK and CD3+ T cell samples because of a higher
number of hypomethylated MVPs in ALK+ tumors (Figure 1B).
However, MVPs differentiating between ALK and T cells
(5,453 probes) showed similar methylation in ALK+ ALCL (Fig-
ure 1C). In total, we identified 2,488 common MVPs in ALK+ and
ALK tumors, compared toperipheral T cells fromhealthydonors
(Figure S2A). The major fraction of MVPs with differential methyl-
ation betweenALK+ andALK tumors (8,147 sites)was hypome-
thylated in ALK+ (Figure S2B) and mainly located in gene bodies
(Figure 1D, toppanel). The frequencyand localizationof hyperme-
thylatedMVPswere highly similar in ALK+ andALK tumors (Fig-
ure 1D, bottompanel). Overall, these data demonstrate thatmany
MVPs are shared between the tumor samples in comparison to
normal CD3+ T cells and unique DNAmethylation characteristics
between ALK+ ALCL and ALK ALCL aremainly based on hypo-
methylated MVPs in ALK+ tumors.
DNAMethylation Patterns of ALCLAre Similar to Thymic
Progenitor Cells
Thymic development involves a complex process of differentia-
tion from progenitor thymocytes to mature T cells and is associ-
ated with dynamic changes in DNA methylation in both mouse
and human organisms. TFs and genes related to TCR signaling
are methylated in progenitor cells and subsequently demethy-
lated at different stages of T cell development (Ji et al., 2010; Ro-
driguez et al., 2015). To compare theALCLmethylome to different
stages of T cell development, we integrated our data with publicly
availablemethylationdataofdifferentdevelopmental T cell stages
(Rodriguez et al., 2015) using principal-component analysis and
hierarchical clustering (p value < 9.4e6). Comparison of the pri-
mary ALK+ and ALK ALCL methylomes with multipotent ETP
(CD34+/CD1a), T cell committed progenitors (CD34+/CD1a+),
pre-TCR T cells, TCR-expressing T (CD4+/CD8+ double positive
[DP]) cells, and single positive (SP) CD4+ or CD8+ cells revealed
that the DNA methylation pattern of ALK+ tumor cells resembled
that of ETP (CD34+/CD1a), whereas the ALKmethylomemore
closely resembled pre-TCR and DP TCR-expressing T cells (Fig-
ure 2A). These data were also reflected in hierarchical clustering
analysis using the top 1% MVPs (4,817 CpGs, p < 9.4e6,
q value = 9.46e4), indicating a close relationship among ALCL
tumor cells, T cell progenitors, and early T cell stages (Figure 2B).
These 4,817 MVPs were located in 2,526 individual genes, 10%
of which were associated with transcription regulator activity
according to gene ontology (GO) analysis (data not shown). This
prompted us to analyze DNA methylation and expression levels
of several T-cell-specific TFs that are essential for defined stages
of thymic T cell development from ETP to SP T cells (Figure 3A).
We detected high levels of DNA methylation in the promoters of
TCF7, GATA3, BCL11B, and LEF1 in ALK+ and ALK tumors
compared to CD3+ T cells from our dataset (Figure S3), which
correlated with their decreased expression levels in tumors
compared toCD3+ T cells, as identified by in silico analysis of pre-
viously publishedALCLgene expressiondata (Figure 3B) (Eckerle
et al., 2009). GATA3 displayed lower promoter DNA methylation
levels in ALK ALCL, but no significantly different GATA3Cell Reports 17, 596–608, October 4, 2016 597
Figure 1. DNA Methylation of ALCL versus
Normal CD3+ T Cells
(A) Venn diagram showing significant MVPs (based
on M values and adjusted p < 0.01) among indicated
groups in comparisons of ALK+, ALK, and normal
CD3+. Numbers indicate unique MVPs of selected
segments; numbers in parentheses indicate total
number of MVPs of the three group comparisons:
ALK+ versus CD3+, ALK versus CD3+, and ALK+
versus ALK.
(B) Hierarchical clustering of the top 31,580 differ-
entially methylated CpG sites detected between
ALK+ and control T cells (color key indicates per-
centage of methylation, from red = 100% methyl-
ation to green = 0% methylation). Sample annota-
tion: blue, tumor; yellow, normal CD3+; red, ALK+
ALCL; green, ALK ALCL.
(C) Hierarchical clustering of the top 5,453 MVPs
detected in control T cells versus ALK ALCL (color
key and sample annotation as in B).
(D) Number and distribution of MVPs between CD3+
T cells and ALK+ or ALK ALCL found at specific
genomic regions and regions around CpG islands.
Hypomethylated MVPs are shown at the top; hy-
permethylatedMVPs are at the bottom. Differentially
methylated sites were obtained after filtering the
data (filtering criteria: adjusted p value < 0.01 and
b-value difference > j0.2j).
See also Figures S1 and S2.expression compared to CD3+ T cells was observed, which is
consistent with the closer relationship of ALK ALCL with DP
TCR-positive cells based on DNA methylation analyses.
To corroborate these findings, we analyzed promoter DNA
methylation of these TFs, as well as LCK promoter DNA methyl-
ation using methylation-sensitive qPCR (ms-qPCR) in a larger
cohort (28 ALK+ and 3 ALK) of ALCL patient samples (Fig-
ure 3C). We also compared these data to DNA methylation
data of the two of the other most common peripheral T cell
lymphoma subgroups, angioimmunoblastic T cell lymphoma
(AITL, 15 samples) and peripheral T cell lymphoma, not other-
wise specified (PTCL-NOS, 18 samples), and to normal CD3+
T cells. DNA methylation levels of both the LCK and the
BCL11B promoters were significantly higher in ALCL compared
to PTCL-NOS and AITL. LEF1 and TCF7 promoters were signif-
icantly hypermethylated in ALCL tumors compared to AITLs and
to normal T cells, but no significant differences in DNA methyl-
ation levels were observed between ALCL and PTCL-NOS sam-
ples, most likely due to heterogeneity in the PTCL-NOS DNA
methylation levels that is reflective of the diversity of this ‘‘waste-
basket’’ disease category.598 Cell Reports 17, 596–608, October 4, 2016Tumor-Cell DNA Methylation
Reprogramming Is Associated with
Epigenetic Modifications at Distinct
Genomic Regions
Weused the Epiexplorer web-based tool to
associate regions of epigenetic reprogram-
ming events in ALCL tumors with publicly
available data (Halachev et al., 2012). As
a control set, we selected the IlluminaCpG annotation and compared our data to signatures from all
tissues available in the Epiexplorer (Figure 4A). Hypomethylated
MVPs in the ALK+ and ALK versus CD3+ dataset were under-
represented at active promoters (7% and 17% versus 30%) and
CpG islands (3% and 6% versus 31%), whereas hypermethy-
lated MVPs showed enrichment at Polycomb-repressed sites
(55% and 53% versus 33%) and CpG islands (45% and 41%
versus 31%) compared to the control set. This is in line with pre-
vious findings showing that cancer-specific DNA hypermethyla-
tion is, besides CpG island methylation, also targeted to already
silenced regions or regions harboring repressive histone marks,
such as Polycomb-repressed genes (Shen and Laird, 2013).
The change from silencing by Polycomb repression in stem
cells to DNA methylation in cancer cells is termed ‘‘epigenetic
switching’’ and has been observed in different cancers (Gal-
Yam et al., 2008; Ohm et al., 2007; Schlesinger et al., 2007; Te-
schendorff et al., 2010; Widschwendter et al., 2007). To test for
the presence of epigenetic switching, we explored DNA methyl-
ation of the HOX gene clusters and other selected Polycomb
group (PcG) target genes in embryonic stem cells (ESCs). The
four HOX gene clusters (A–D) are known PcG targets in ESCs.
Figure 2. Comparison of Different Develop-
mental Stages of Thymocytes with ALCL
Tumor Cells
(A) Left panel: principal-component analysis of
thymic T cell subsets in comparison to ALK+ and
ALK tumor cells and peripheral CD3+ T cells (p <
9.4e6, q value = 9.46e4). Right panel: thymic
developmental stages from ETPs (CD34+/CD1a) to
SP CD4+ or CD8+ cells.
(B) Hierarchical clustering of the top 1%of all probes
of thymic subsets, ALK+ and ALK tumor cells, and
peripheral CD3+ T cells (4,817 CpG sites) (p <
9.4e6, q value = 9.46e4). Data were normalized
using Qlucore software, as described in the Sup-
plemental Experimental Procedures. Global
normalization was used to center the b values for
each sample to a mean of 0 (variance = 1) to adjust
for differences in signal intensities of the different
Infinium BeadChips. Color key from green = 2 (0%
methylation) to red = +2 (100% methylation).As exemplified by theHOXD cluster, we detected DNA hyperme-
thylation at all four clusters and additional homeobox genes in
ALK+ and ALK ALCL tumor samples (Figure 4B; Figure S4).
Comparative analysis of these ALCL hypermethylated CpG
sites with ENCODE chromatin immunoprecipitation sequencing
(ChIP-seq) data showed that PcG occupancy, as defined by his-
tone H3 lysine trimethylation (H3K27me3) and EZH2 binding, are
present in ESCs and GM12878 lymphoblastoid cells at these
sites (Bernstein et al., 2012; ENCODE Project Consortium,
2012). In contrast to the situation in ESCs and lymphoblastoid
cells, but in line with epigenetic switching, we detected more
than 10-fold enrichment of histone H3K9me3, a repressive chro-
matin mark that is frequently found in heterochromatic regions
and regions with high DNA methylation, at HOXA9 and HOXD3
promoters and a relative depletion of PcG-related H3K27me3
in the ALK+ cell line SU-DHL-1 (Figure 4C). H3K4me3, which
is associated with active promoters, was also depleted at
these loci.
Altogether, these data show a significant difference in
genome-wide DNA methylation between ALCL tumors and
normal activated T cells in regions that control transcriptional ac-
tivity of genes, CpG islands and PcG-targeted regions in ESCs,Cewhich appears to be a common feature of
epigenetic tumor cell reprogramming.
Identification of Differentially
Methylated Regions between Tumor
and Normal T Cells and Their
Relation to Altered Gene Expression
Next, we sought to identify distinct
genomic regions spanning multiple CpG
sites that showed differential methylation
between tumor and healthy control sam-
ples. To identify such differentially methyl-
ated regions (DMRs) between samples,
mean DNA methylation levels of multiple
probes were calculated for distinct regionsbased on the annotated Illumina categories. These categories
included gene promoters spanning regions 1,500 and 200 bp
upstream of transcription start sites (TSSs) (TSS1500 and
TSS200), 50 UTRs, first exons, gene bodies, 30 UTRs, CpG
islands, CpG island shores, and CpG island shelves (defined
as regions surrounding CpG islands). Data were filtered accord-
ing to criteria expected to reflect biologically significant differ-
ences in DNA methylation (adjusted p value < 0.05; b-value
differenceR 0.15) (Figure 5A). Generally, the numbers of hyper-
methylated and hypomethylated DMRs in ALK+ and ALK sam-
ples compared to controls were similar, except for more hypo-
methylated DMRs located in TSSs (674 ALK+, 468 ALK),
gene bodies (462 ALK+, 194 ALK), and regions adjacent to
CpG islands (e.g., shelves, and shores) (658 on average in
ALK+, 384 on average ALK) in ALK+ samples. ALK samples
in general showed larger numbers of hypermethylated DMRs,
especially in the 50 UTR and first exon region and in CpG island
shores. Regarding CpG islands, hypermethylated DMRs were
detected in both ALK+ and ALK samples (1,126 ALK+, 645
ALK), but only 52 and 40 CpG islands, respectively, were hypo-
methylated. This was expected, because CpG islands are usu-
ally kept free of methylation in normal somatic cells, independentll Reports 17, 596–608, October 4, 2016 599
Figure 3. Silencing of T-Cell-Specific TFs in
ALCL
(A) Serial stages of thymic T cell development are
driven by specific TFs. DN, double negative.
(B) Gene expression differences of indicated TFs
between ALK+ and ALK ALCL compared to CD3+
T cells.
(C) DNA methylation levels of promoter regions of
indicated genes as determined by quantitative
methylation ms-qPCR in 28 ALK+ ALCL, 3 ALK
ALCL, 15 AITL, and 18 PTCL-NOS tumor samples,
with 6 healthy CD3+ samples as controls. Samples
were analyzed by one-way ANOVA (p < 0.05)
followed by pairwise comparisons to the control
group using unpaired t tests. Values are shown as
mean ± SEM.
See also Figure S3.of the expression level of their underlying gene (Jones et al.,
1990). Most hypomethylated islands were located in non-pro-
moter CpG islands in transcribed regions at the 30 end of genes
or in gene deserts. Almost no significant DMRs could be identi-
fied between ALK+ and ALK samples, suggesting that no ALK-
specific influence on promoter DNA methylation, and thus gene
expression, can be detected (data not shown).
To identify biologically relevant functions and pathways
affected by DNA methylation changes, we performed GO term
analysis on differentially methylated gene promoters using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (Huang et al., 2009a, 2009b). We interrogated the600 Cell Reports 17, 596–608, October 4, 2016database for significant differentially meth-
ylated genes with hypermethylated or hy-
pomethylated promoters, assuming that
altered gene promoter DNA methylation is
associated with changes in gene expres-
sion between healthy and tumor samples.
Promoter DNA methylation in both ALK+
and ALK tumors showed a large overlap
of enriched GO terms. Hypomethylated
promoters were implicated in biological
processes such as immune or defense
response (Figure 5B; Table S1). Hyperme-
thylated promoters of both tumor groups
were associated with high significance
with GO terms related to immune system
processes such as ‘‘regulation of immune
cell activation,’’ specifically ‘‘T cell activa-
tion’’ (Figure 5B; Table S1).
To determine the relationship of DNA
methylation changes and significant alter-
ations in biological activity, we evaluated
the correlation of promoter DMRs with
changes in gene expression between
CD3+ T cells and ALK+ and ALK ALCL.
To this end, we used publicly available
gene expression data on ALK+ and ALK
ALCL and CD4/CD8 T cell subsets and
correlated these to DMRs in promotersidentified from our data (TSS200, TSS1500) (Figure 5C) (Eckerle
et al., 2009). In ALK+ tumors, 65 of 501 (13%) significantly hyper-
methylated TSSs were found to be significantly downregulated,
and 93 of 674 (14%) hypomethylated TSSs were upregulated by
more than 1.5-fold. Similarly, in ALK tumors, 84 of 674 (12%)
hypermethylated and 55 of 468 (12%) hypomethylated DMRs
were down- and upregulated by more than 1.5-fold, respec-
tively. Top differentially methylated and deregulated genes are
listed in Table S2. GO term analysis of this dataset of both differ-
entially methylated and deregulated genes confirmed their asso-
ciation with immune cell-related processes such as T cell activa-
tion for hypermethylated silenced genes and defense response
Figure 4. Genomic and Epigenomic Features of Differentially Methylated CpG Sites
(A) Epiexplorer analysis using indicated genomic features of hypermethylated (red) and hypomethylated (green) CpG sites for ALK+ and ALK ALCL compared to
CD3+ T cells in relation to all CpG sites on the Illumina 450k array (black).
(B) Epigenetic switching is detected at the HOXD cluster in ALK+ and ALK ALCL at regions that show H3K27me3 and EZH2 occupancy by ChIP-seq in ESCs
and in GM12878 lymphoblastoid cells. Top tracks (blue): differential methylation of ALK+/ALK ALCL versus CD3+ T cells. Middle tracks: University of California
Santa Cruz (UCSC) gene annotation track, where green boxes are CpG islands. Lower tracks: enrichment of EZH2 and H3K27me3 in lymphoblastoid cells (red)
and ESCs (green).
(legend continued on next page)
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for hypomethylated and upregulated genes for both tumor sub-
groups (Table S3). In addition, we identified 25 and 17 hyperme-
thylated gene promoters with increased gene expression, aswell
as 20 and 28 hypomethylated gene promoters with decreased
expression, in ALK+ and ALK samples, respectively. However,
this discrepancy may be because all affected genes were repre-
sented by alternative transcripts, whereas the altered DNA
methylation was only identified in one specific isoform that might
not represent the isoform determined in the expression dataset.
Altogether, these data show that differential methylation
of genes in ALCL affects mainly biological processes related to
immune cell function, which reflects the characteristics of the
transformed T cells, and is associated with altered gene expres-
sion in approximately 12% of hypo- and hypermethylated genes
in both tumor subgroups.
Major T-Cell-Specific Pathways and Networks Are
Associated with Altered DNA Methylation
To obtain a better understanding of cellular networks and path-
ways affected by altered DNA methylation in ALCL, we next per-
formed Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.
com). Due to the high similarity of promoter DMRs in ALK+ and
ALK samples, we used the significant 194 hypomethylated
and 186 hypermethylated overlapping promoters from both
tumor subgroups. We identified the TCR and CTL4-A pathways
as being among those canonical pathways most significantly
affected by DNA hypermethylation (Figure 6A). Seven genes
implicated in the TCR and CTLA-4 signaling pathways (CD3,
CD28, CTLA-4, LCK, GADS, SHP1, and LYP) showed hyperme-
thylation in ALCL samples. These data are in line with a previous
report of DNA hypermethylation of several TCR pathway genes
in ALK+ ALCL (Ambrogio et al., 2009) (Figure S5).
Among hypomethylated gene promoters, TREM1 signaling
scored as the top canonical pathway (Figure S6). TREM1 is a
triggering receptor promoting cytokine and chemokine produc-
tion (Bouchon et al., 2000). This finding supports the reported
distinct cytokine expression profiles for ALK+ and ALK ALCL
tumors (Al-Hashmi et al., 2001; Iqbal et al., 2010; Lamant et al.,
2007).
Using the Regulator Effects feature in IPA, we identified regu-
lators and functions strongly linked with T cell accumulation,
tumor cell proliferation, immune cell function, and cell expansion.
In summary, known ALCL driving factors, including CEBPB,
nuclear factor kB (NF-kB), mitogen-activated protein kinase
(MAPK), and STAT3, were suggested as upstream regulators tar-
geting the affected hypo- and hypermethylated genes identified
from our datasets (Figure S7).
Enrichment of TF Binding Site Motifs in TF Binding Site
Motifs
Because deregulated TFs play a key role in ALK-dependent
transformation and may be involved in reshaping the ALCL epi-(C) ChIP interrogating repressive histonemarks (H3K9me3, H3K27me3) and active
DHL-1 cells.GAPDH is shown as control for an active region, SAT2 is control for a
is control positive control for H3K27me3 occupancy. H3global indicates a control
of three replicates.
See also Figure S4.
602 Cell Reports 17, 596–608, October 4, 2016genome, we next sought to evaluate whether changes in the
ALCL epigenome are related to specific TFs in primary ALCL.
To identify enrichment of TF binding sites in the vicinity of CpG
sites that are hypomethylated in ALK+ and ALK ALCL tumors,
we searched for common DNA sequence motifs in windows of
100 bp surrounding significant MVPs (28,255 hypomethylated
CpG sites in ALK+ ALCL tumors and 1,291 hypomethylated
CpG sites in ALK ALCL tumors) using the MEME-ChIP tool
and related applications within the Multiple EM for Motif Elicita-
tion (MEME) web-based suite (Bailey et al., 2009;Machanick and
Bailey, 2011). The top motif with the highest frequency in hypo-
methylated sites of ALK+ and in ALK ALCL was a motif of 8 ba-
ses (e values 5.91e3 and 5.19e2, respectively) (Figure 6B).
This motif is similar to the consensus motif of the basic leucine
zipper TFs such as JUN, JUNB, JUND, and FOS, which belong
to the AP1 family of TFs. ChIP in ALK+ Karpas-299 cells revealed
binding of the AP1 factor JUNB at distinct top hypomethylated
promoters, including SERPINA1, LYN, and TLR6, with putative
AP1 binding sites (Figure 6C). ALCLs are highly dependent on
JUNB, as indicated by decreased cell population doublings after
short hairpin RNA (shRNA)-mediated depletion of JUNB in Kar-
pas-299 cells. This reduction of cell doubling was mainly due
to cell-cycle arrest in the G0/G1 phase and increased apoptosis
(Figure S8). Altogether, our data show that AP1 is a major down-
stream regulator of NPM-ALK ALCL signaling, which is reflected
in lower DNAmethylation levels of genes containing AP1 binding
sites in ALCL.
DISCUSSION
In cancer cells, changes in the methylome comprise focal DNA
hypermethylation, together with genome-wide DNA hypomethy-
lation of genomic regions (Egger et al., 2004). These changes
depend on general aspects of cancer development, the cell of
origin, and individual characteristics obtained by the malignant
cell during transformation. For ALK+ ALCL, which largely de-
pends on the oncogenic driver NPM-ALK, and ALK ALCL, for
which no single defined oncogenic driver has been identified
as yet, no systematic analysis of global DNA methylation has
been performed so far. This prompted us to study DNA methyl-
ation differences between the two tumor groups and to investi-
gate the association of oncogene signaling and epigenetic alter-
ations between normal T cells and lymphoma.
Regarding the origin of ALK+ and ALK ALCL, our data
suggest that progenitor thymic T cell stages, not mature SP
CD4+ or CD8+ cells, are the sources of ALCL, because both
ALK+ and ALK ALCL DNA methylation patterns were highly
similar to discrete developmental stages of thymocytes. Both
ALK+ and ALK lymphomas are classified, together with AITL
and PTCL-NOS, as peripheral T cell lymphomas, which have—
in contrast to, e.g., lymphoblastic lymphoma—by definition a
post-thymic origin. However, our findings, which are based onhistonemarks (H3K4me3) atHOXA9 andHOXD3 gene promoters in ALK+ SU-
heterochromatic region, NCR is control for a negative control region, and PLAU
ChIP for global H3 occupancy. Values are means ± SD. Each value is the mean
Figure 5. Characterization of DMRs
(A) Identification of DMRs, calculated from mean
b values of all CpGs annotated to a distinct
genomic region, between ALK+ (left) and ALK
(right) versus CD3+ T cells (p value < 0.05; b-value
differenceR 0.15). TSS includes CpGs within either
200 or 1,500 bp of the TSS. Hypermethylated DMRs
are depicted in red; hypomethylated DMRs are in
green.
(B) GO term analysis using the DAVID web-based
tool. Significant GO terms (adjusted p < 0.05) are
highly similar in ALK+ and ALK tumors.
(C) Correlation of genes with differentially methyl-
ated promoters with gene expression profiles of
ALK+ and ALK ALCL and T cells. Blue, genes
downregulated in ALCL versus T cells; red, genes
upregulated in ALCL versus T cells.
Hypermethylated TSS, genes showing higher
methylation in both groups within their promoters;
hypomethylated TSS, genes with lower methylation
in their promoters in both groups. See also Tables
S1, S2, and S3.comparison of DNA methylation patterns among different T cell
differentiation stages, indicate that T cell transformation in
ALK+ ALCL may occur in progenitor cells rather than in mature
T cells and are in line with two papers reporting that ALCLs
have a primitive origin and arise in thymocytes before TCR b-re-
arrangement (Malcolm et al., 2016; Moti et al., 2015). We found
ALK+ ALCL DNA methylation patterns to be in proximity to
CD34+/CD1a patterns corresponding to the ETP stage and
DNA methylation patterns of ALK ALCL to be close to thoseCeof DP (CD4+ CD8+) or pre-TCR-positive
T cells. The ETP stage still has the potential
to differentiate into B cell, myeloid, natural
killer (NK), and dendritic cell (DC) lineages,
and the close relationship of ALK+ ALCL to
this stage might explain why myeloid anti-
gen expression is frequently observed in
ALK+ ALCL, thereby confusing an ALCL
diagnosis (Popnikolov et al., 2000). In line
with this, we found the TREM1 signaling
pathway to be affected by DNA hypome-
thylation. TREM1 is a triggering receptor
expressed on myeloid cells with a func-
tion in stimulating neutrophil- and mono-
cyte-mediated inflammatory responses by
triggering the release of pro-inflammatory
cytokines and chemokines (Arts et al.,
2013; Ford and McVicar, 2009). Thus,
TREM1 signaling might be a consequence
of lacking T cell commitment at the precur-
sor stage following transformation by ALK
and other oncogenic events. The peak
occurrence of ALK+ ALCL in children and
young adolescents, when thymic T cell
development is most prominent, would
lend support to an early origin of ALK+
ALCL. However, we cannot exclude thatthe similarity of the ALCL epigenome to thymic T cell subsets
is due to reprogramming of mature T cells by oncogenic
signaling and a regression to a progenitor phenotype.
In addition, ALK+ ALCL and ALK ALCL revealed unique
promoter DNA methylation of T-cell-specific TFs, thereby
clearly distinguishing them from PTCL-NOS and AITL. Thymic
T cell development follows a tightly regulated sequential process
involving different stages, from early T cell commitment, to TCR
rearrangement and b-selection, through to positive selection ofll Reports 17, 596–608, October 4, 2016 603
Figure 6. Canonical Pathways Are Affected by Differentially Methylated Genes
(A) Multiple genes of the TCR pathway are hypermethylated in ALK+ and ALK ALCL (red, significantly hypermethylated genes; green, significantly hypo-
methylated genes; adjusted p value < 0.05; b-value differenceR 0.15). The pathway was generated through the use of QIAGEN’s IPA.
(B) DNA sequence motif identified by unbiased motif search in regions adjacent to hypomethylated CpGs in ALK+ and ALK ALCL (top) compared to the AP1
consensus motif (bottom).
(C) ChIP for JUNB occupancy at hypomethylated ALCL promoters with putative AP1 binding sites. PDGFRb, positive control. ChIP was normalized to a negative
control region in the 30 end of the PDGFRb gene containing no AP1 motif. Values are means ± SEM. Each value is the mean of three replicates.
See also Figures S5–S8.SP CD4+ and CD8+ T cells. As shown by a study, normal T cell
differentiation and TCR function are accompanied by specific
DNA methylation changes, and TF demethylation, which is irre-
versible in most cases, is observed during the developmental
process (Rodriguez et al., 2015). In contrast to normal differenti-604 Cell Reports 17, 596–608, October 4, 2016ation, and specific for ALCL when compared to AITL and PTCL-
NOS, we identified DNA hypermethylation and repression of
the T-cell-specific TFs LEF1, TCF7, GATA3, and BCL11B in
our sample cohort. This may indicate that TF demethylation
required during normal differentiation does not take place or is
profoundly perturbed in ALCL. In healthy T cells, the TFs found to
be methylated in ALCL normally drive T cell development,
together with NOTCH1 signaling. LEF1 and TCF7 are essential
for the induction of T-cell-specific genes, including the TCRa
enhancer (Okamura et al., 1998). In addition, the TCF7 target
BCL11B, which is expressed during the early DN2 stage of
mouse thymic development, is needed for T cell commitment
(Li et al., 2010). The TF GATA3, which is crucial not only for
T cell survival and commitment in early stages but also for the
transition to the DP state in later stages (Yui and Rothenberg,
2014), was not hypermethylated in ALK ALCL, and there was
no expression difference when compared to CD3+ T cells, corre-
sponding to the DNA methylation phenotype of ALK ALCL
tumors that more closely resemble the DP stage of thymic devel-
opment. This might indicate that ALK ALCLs, which predomi-
nantly occur in older patients, are not originating in thymic
T cells. Overall, DNA methylation analysis of distinct T-cell-spe-
cific TFs could be used for diagnostic purposes for T cell lym-
phoma classification.
The unique ALCL-specific promoter DNA methylation of these
key T cell TFs, resembling that of early T cell stages, suggests
that differentiation to T cells with an activated phenotype is likely
not driven by T cell TFs in ALCL but rather might be induced by
oncogenic signaling by ALK and other oncogenes at this specific
T cell stage. The observation of major in-frame clonal TCRa rear-
rangements in the absence of TCRb clonal rearrangements in
human ALK+ patients’ samples demonstrates that abnormal
T cell differentiation processes take place in the thymus at these
stages (Malcolm et al., 2016). In addition, data in mice suggest
that some form of the TCR seems to be a prerequisite for thymic
egress and for the activated T cell phenotype of ALCL, but it has
been shown that the TCR has to be subsequently downregulated
for lymphomagenesis by epigenetic silencing, which is also sup-
ported by our data (Ambrogio et al., 2009; Malcolm et al., 2016).
Besides the TCR, we find the T-cell-specific receptor CTLA-4 to
be hypermethylated and repressed in ALCL. CTLA-4 is a recep-
tor normally expressed on activated T cells that inhibits T cell
activation by reducing interleukin-2 (IL-2) production and inter-
leukin-2 receptor (IL-2R) expression and causing cell-cycle ar-
rest (Alegre et al., 2001). Its activation is associated with reduced
activation of the MAPKs ERK and JNK and inhibition of the TFs
NF-kB, NFAT, and AP1, which play a major role in ALK-depen-
dent transformation of T cells, suggesting that CTLA-4 downre-
gulation by DNA methylation contributes to intact ALK signaling.
Its importance for regulation of T cell proliferation has also been
demonstrated in murine knockout models, because Ctla-4 dele-
tion led to accumulation of T lymphocytes in peripheral lymphoid
and solid organs, thus resembling a T cell lymphoproliferative
disorder (Tivol et al., 1995; Waterhouse et al., 1995). Thus, if
the cell of origin in ALK+ ALCL is an ETP, survival or bypass of
subsequent selection processes in the thymus may be accom-
plished by oncogenic signaling processes induced by ALK
without the aid and presence of T-cell-specific TFs. In addition,
deregulation of the TCR and CTLA-4 signaling could be an oblig-
atory consequence of ALK signaling to enable the transgression
of the disease to the periphery. Thus, reactivation of the TCR
pathway and CTLA-4 signaling using DNA methyltransferase
inhibitors might provide a therapeutic option for ALCL patients.Overall, our data show that ALK+ ALCL and ALK ALCL har-
bor similar methylation patterns relevant for gene expression
compared to CD3+ cells. In direct comparison to ALK ALCL,
we observed that a larger number of certain genomic regions
such as gene bodies were hypomethylated in ALK+ tumors,
but surprisingly, we could not identify an ALK+-specific DNA
methylation signature at gene promoters in ALK+ samples.
This implies that signaling through hyperactive ALK does not
lead to a distinct biologically relevant epigenetic change in
ALK+ ALCL compared to ALK ALCL. The overall similar
methylation changes may be explained by analogous oncogenic
driving forces, such as specific TFs, that are activated or inacti-
vated in both ALK+ ALCL and ALK ALCL. For example, NPM-
ALK has been shown to induce promoter DNA methylation of tu-
mor suppressors via its downstream target STAT3, which is also
a highly relevant TF in ALK ALCL (Crescenzo et al., 2015).
Another common major oncogene-induced transcription factor
in both ALK+ ALCL and ALK ALCL is AP1 (Laimer et al.,
2012; Staber et al., 2007). In our data, we observed conserved
AP1 TF binding sites enriched when situated close to hypome-
thylated CpG sites in ALCL tumors. Enrichment of AP1 at hypo-
methylated CpG sites and protection from DNA methylation by
the AP1 family member c-Jun has been described in colon can-
cer and in BCR-ABL-induced lymphoid leukemia (Berman et al.,
2011; Kollmann et al., 2011). In linewith this, we detected binding
of the AP1 family member JunB at hypomethylated CpG sites in
ALK+ cells and identified TFs such as STAT3, NF-kB, CEBPB,
and MAPK as upstream transcriptional regulators of genes
with hypo- and hypermethylated promoters. These findings indi-
cate that specific TFs are associated with alterations in DNA
methylation in both ALK+ ALCL and ALK ALCL.
Despite the distinct DNA methylation changes, especially in
ALK+ ALCL, suggesting a thymic progenitor, it cannot be ruled
out that mature transformed T cells turn on an epigenomic pro-
gram that may lead to reprogramming of the DNA methylome
to that of a thymic progenitor. We detected such epigenetic
reprogramming at PcG regions, which contain the passive
H3K27me3 mark in stem cells. PcG target genes are involved
in developmental processes and are often set to a poised state
in ESCs, but they can be silenced at later stages of differentia-
tion depending on the presence of repressive PcG complexes
and histone marks. DNA methylation at these bivalent chro-
matin domains has been observed in a multitude of cancers
and has been discussed as an epigenetic stem cell signature
of cancer, resembling reprogramming of the cancer cell epige-
nome to a more dedifferentiated state (Gal-Yam et al., 2008;
Lehnertz et al., 2003; Ohm et al., 2007; Tachibana et al.,
2008; Vire´ et al., 2006; Widschwendter et al., 2007). This gain
of methylation at genes important for stemness and differentia-
tion could also explain the increased methylation detected at
T-cell-specific TFs in ALCL. Still, no hypermethylation at these
sites is detected in PTCL-NOS and AITL, indicating that pro-
moter DNA methylation gain at T-cell-specific TFs is specific
for ALCL and not a universal feature of other peripheral T cell
lymphomas.
Altogether, our study identified distinct DNA methylation
changes in ALK+ and ALK ALCL tumors that are reflective of
a thymic origin of ALCL and include major TFs and pathwaysCell Reports 17, 596–608, October 4, 2016 605
related to immune cell function and development. We did not
observe direct evidence for NPM-ALK-specific epigenetic alter-
ations in our data, although deregulation of TFs important during
T cell differentiation and development is accomplished via
DNA hypermethylation and ALCL-specific TFs are involved in
epigenetic changes of tumor cells at sites of DNA hypo- and
hypermethylation.
EXPERIMENTAL PROCEDURES
Information on cell lines, DNA preparation, and bioinformatic analyses can be
found in the Supplemental Experimental Procedures.
Human Patient Samples and Controls
Archived fresh frozen tissue from ALK+ and ALK patients (four female and
one male each, tumor content > 90% histopathologically verified), and blood
samples for CD3+ T cell isolation from five healthy female patients as controls
were obtained in an anonymized fashion from the Institute of Clinical Pathology
(Medical University of Vienna) and the St. Anna Children’s Hospital. For clinico-
pathological characteristics, see Table S4. Archived formalin-fixed paraffin-
embedded (FFPE) tumors from 28 ALK+ and 3 ALK ALCL patients, 18
PTCL-NOS patients, and 15 AITL patients were also obtained in a blind and
randomized fashion from the Institute of Clinical Pathology. The study protocol
for the use of patient tissues was approved by the Institutional Ethics Commit-
tee of the Medical University of Vienna (1224/2012).
Isolation of CD3+ Cells from Whole-Blood Samples
Peripheral blood mononuclear cells (PBMCs) were isolated by density centri-
fugation of whole-blood samples (Lymphoprep) and bound to CD3 microbe-
ads (Miltenyi). Bound cells were loaded onto an equilibrated MACS LS sepa-
ration column (Miltenyi) and washed, and CD3+ cells were eluted according
to the supplier’s protocol.
DNA Methylation Analysis by Illumina Infinium
HumanMethylation450 BeadChips
Before hybridization onto arrays, 0.5 mg of each DNA sample (5 ALK+ frozen
tumors, 5 ALK frozen tumors, and 5 CD3+ T cells) were bisulfite converted
with the EZ DNA Methylation Kit (Zymo Research) according to the manufac-
turer’s protocol and Illumina’s recommendations. Bisulfite conversion was
carried out overnight in a thermocycler at 95C for 30 s and then 50C for
60 min (16 cycles), and bisulfite DNA was purified and eluted in 12 mL of sterile
water. Then, 4 mL of bisulfite-converted DNA were subjected to genome-wide
amplification, following an isothermal incubation step at 37C for 20 hr. After
genome-wide amplification, the DNA was enzymatically fragmented, purified,
and precipitated. The precipitated DNA was resuspended in 42 mL RA1 buffer
and denatured at 95C for 20 min. The denatured DNA samples (12 mL) were
applied to the BeadChip for hybridization at 48C for 20 hr. Subsequently,
non-hybridized fragments were removed by several washing steps. Details
on array data normalization and processing can be found in the Supplemental
Experimental Procedures. Illumina methylation data comparing different
thymic T cell subsets were downloaded from the NCBI GEO: GSE55111.
ms-qPCR
The DNA sample (0.5 mg of 5 ALK+ frozen tumors, 6 CD3+ T cells, 23 ALK+
paraffin-isolated tumors, 3 ALK paraffin-isolated tumors, ALK+ Karpas-299
cells, M.SssI-treated control DNA [Zymo Research] and unmethylated control
DNA [Zymo Research]) were subjected to bisulfite conversion with the EZ
DNA Methylation Kit according to the manufacturer’s protocol. Methylation-
specific primers were designed with MethPrimer (http://www.urogene.org/
methprimer). Primers are listed in the Supplemental Experimental Procedures.
ms-qPCRs were performed according to the MethyLight protocol (Campan
et al., 2009) but using SYBR green instead of TaqMan probes for quantifica-
tion. PMR (percentage of methylated reference) values were calculated ac-
cording to the following formula: 100 3 [(Gene-X mean value)sample / (Alu
mean value)sample] / [(Gene-X mean value)M.SssI / (Alu mean value)M.SssI].606 Cell Reports 17, 596–608, October 4, 2016Gene Expression Analysis
Gene expression data from ALCL tumors and normal T cells were obtained
from GEO: GSE14879.
ChIP and qPCR
ChIP was performed as described (Gal-Yam et al., 2008). Approximately
100 mg of chromatin isolated from 107 Karpas-299 or SU-DHL-1 cells were
incubated with 50 mL of Dynabeads proteinG (Life Technologies) for 1 hr at
4C and then with 10 mg of anti-JUNB (Santa Cruz, sc-73X) or 1 mg of anti-his-
tone H3 (Abcam, ab1791), anti-H3K4me3 (Abcam, ab8580), anti-H3K9me3
(Abcam, ab8898), anti-H3K27me3 (Abcam, ab6002), or control immunoglob-
ulin G (IgG) (Santa Cruz, sc-2027) overnight. Bound chromatin was washed,
eluted, and de-cross-linked, and DNA was isolated by phenol-chloroform
extraction after protein digestion. Primer sequences are listed in the Supple-
mental Experimental Procedures.
Knockdown of JunB by shRNA
Knockdown experiments were performed using lentivirus-mediated transduc-
tion of Karpas-299 with shRNA vectors as detailed in the Supplemental Exper-
imental Procedures.
ACCESSION NUMBERS
The accession number for the Illumina methylation data reported in this paper
is GEO: GSE66881.
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